NBE-Therapeutics

Switzerland
Breíl, Grisons, Switzerland, 4057

Company profile

NBE-Therapeutics company profile

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Business identity

Contact email
[email protected]
Phone number
+41616332230
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Postal code
4057
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
5
Total equity funding
$65.7M
Last funding
Series C / $22M / 2020-01-10
Last equity funding
Series C / $22M
Investors
4
Lead investors
3
Founders
1
Articles
17
Exited on
2020-12-10

Founders and investors

Founders

Ulf Grawunder

Lead investors

Boehringer IngelheimBoehringer Ingelheim Venture FundPPF Group

Investors

Boehringer IngelheimBoehringer Ingelheim Venture FundNovo HoldingsPPF Group